How does SLZA's PB Ratio compare to its peers?

SLZA is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (5.1x).

How does SLZA's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

SLZA is good value based on its Price-To-Book Ratio (0.7x) compared to the European Pharmaceuticals industry average (2.3x).

What is SLZA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate SLZA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of SLZA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate SLZA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Enveric Biosciences (DB:SLZA) - Stock Price, News & Analysis

SLZA Stock Overview

A biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. More details

SLZA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 19.4% per year over past 5 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap (€3M)

+ 2 more risks

Enveric Biosciences, Inc. Competitors

Biofrontera

XTRA:B8FK

€15.8m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Enveric Biosciences
Historical stock prices
Current Share Price	US$0.30
52 Week High	US$2.38
52 Week Low	US$0.30
Beta	0.47
11 Month Change	-35.86%
3 Month Change	-32.97%
1 Year Change	-76.54%
33 Year Change	-99.49%
5 Year Change	n/a
Change since IPO	-99.80%

Recent updates

Shareholder Returns

	SLZA	DE Pharmaceuticals	DE Market
7D	-4.5%	1.4%	0.8%
1Y	-76.5%	-18.4%	9.1%

Return vs Industry: SLZA underperformed the German Pharmaceuticals industry which returned -18.4% over the past year.

Return vs Market: SLZA underperformed the German Market which returned 9.1% over the past year.

Price Volatility

Is SLZA's price volatile compared to industry and market?
SLZA volatility
SLZA Average Weekly Movement	13.1%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: SLZA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: SLZA's weekly volatility has decreased from 33% to 13% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
n/a	7	Joseph Tucker	www.enveric.com

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.

Enveric Biosciences, Inc. Fundamentals Summary

How do Enveric Biosciences's earnings and revenue compare to its market cap?
SLZA fundamental statistics
Market cap	€2.74m
Earnings (TTM)	-€9.41m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Is SLZA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLZA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$9.86m
Earnings	-US$9.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.10
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did SLZA perform over the long term?

See historical performance and comparison

SLZA Stock Overview

Risk Analysis

Enveric Biosciences, Inc. Competitors

XTRA:B8FK

€15.8m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.9m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

New major risk - Financial position

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Recent updates

Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

New major risk - Financial position

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

New major risk - Share price stability

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

New major risk - Share price stability

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

High number of new and inexperienced directors

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

Shareholder Returns

Price Volatility

About the Company

Enveric Biosciences, Inc. Fundamentals Summary

0.0x

-0.3x

Earnings & Revenue